Pharmacokinetic, Safety, and Efficacy of B/F/TAF in HIV-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimestersmidwayadmin2019-07-10T16:32:13+00:00
Pharmacokinetic, Safety, and Efficacy of B/F/TAF in HIV-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters
GS-US-380-5310 · Trial ·
Major Inclusion/Exclusion Criteria:
- HIV RNA <50 for 6 months
- Pregnancy between 12 weeks and 31 weeks at the time of Screening
- GFR >90
- No Hepatitis B Infection